3Daughters, a clinical development company dedicated to advancing women’s healthcare, has announced the successful completion of an oversubscribed seed financing round, raising $4.7 million. This round saw participation from existing investors including Thairm Bio, Argosy Foundation, Wexford Science and Technology, UMass Amherst, and new undisclosed investors.
Mary Beth Cicero, CEO of 3Daughters, commented: “We are thrilled by the overwhelming response from both our existing and new investors who share our determination and dedication to improving therapies for women, starting with our advanced IUD and integrated system for insertion and retrieval. Notably, this oversubscribed round supports our preclinical development through an IND filing in early 2025, a major milestone in our development timeline.”
Research indicates that over 275 million women worldwide use intrauterine devices (IUDs), with copper IUDs being the most popular choice for non-hormonal, long-acting, and reversible contraception. 3Daughters’ lead asset, 3D-001, is a frameless, non-hormonal, magnetic IUD that self-assembles in the uterus and conforms to a woman’s body. 3D-001 is paired with a patented inserter and retriever designed as an integrated system to eliminate the three major pain points during the IUD insertion process.
